| Autor: |
Anna R. Giuliano, Raphael Viscidi, B. Nelson Torres, Donna J. Ingles, Staci L. Sudenga, Luisa L. Villa, Maria Luiza Baggio, Martha Abrahamsen, Manuel Quiterio, Jorge Salmeron, Eduardo Lazcano-Ponce |
| Jazyk: |
angličtina |
| Rok vydání: |
2015 |
| Předmět: |
|
| Zdroj: |
Papillomavirus Research, Vol 1, Iss , Pp 109-115 (2015) |
| Druh dokumentu: |
article |
| ISSN: |
2405-8521 |
| DOI: |
10.1016/j.pvr.2015.06.007 |
| Popis: |
Background: Protection from naturally acquired human papillomavirus (HPV) antibodies may influence HPV infection across the lifespan. This study describes seroconversion rates following genital, anal, and oral HPV 6/11/16/18 infections in men and examines differences by HPV type and anatomic site. Methods: Men with HPV 6/11/16/18 infections who were seronegative for those genotypes at the time of DNA detection were selected from the HPV Infection in Men (HIM) Study. Sera specimens collected ≤36 months after detection were analyzed for HPV 6/11/16/18 antibodies using a virus-like particle-based ELISA. Time to seroconversion was separately assessed for each anatomic site, stratified by HPV type. Results: Seroconversion to ≥1 HPV type (6/11/16/18) in this sub-cohort (N=384) varied by anatomic site, with 6.3%, 18.9%, and 0.0% seroconverting following anal, genital, and oral HPV infection, respectively. Regardless of anatomic site, seroconversion was highest for HPV 6 (19.3%). Overall, seroconversion was highest following anal HPV 6 infection (69.2%). HPV persistence was the only factor found to influence seroconversion. Conclusions: Low seroconversion rates following HPV infection leave men susceptible to recurrent infections that can progress to HPV-related cancers. This emphasizes the need for HPV vaccination in men to ensure immune protection against new HPV infections and subsequent disease. Keywords: HPV, Men, Seroconversion, HPV antibodies, Human papillomavirus |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
